AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BeOne Medicines Ltd. Director's Dealing 2025

Mar 8, 2025

30073_dirs_2025-03-07_3cfe3b2e-ddc5-469b-acfe-5546483b3576.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BeiGene, Ltd. (BGNE)
CIK: 0001651308
Period of Report: 2025-03-05

Reporting Person: Rosenberg Aaron (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-03-05	Ordinary Shares	A	48581	—	Acquired	167128	Direct

Footnotes

F1: Represents the total number of ordinary shares underlying the performance share units earned by Reporting Person. The earned performance share units will vest in 2027, subject to the Reporting Person continuing to provide service to the Company through such vesting date. Unvested securities are subject to accelerated vesting upon certain termination events.